Review highlights advances in Epstein–Barr virus vaccine development mechanisms and future challenges.
Epstein–Barr virus (EBV) is a ubiquitous oncogenic virus linked to malignancies and autoimmune diseases. No licensed vaccines are currently available. Recent advances in EBV biology have enabled rational antigen selection and accelerated development of multivalent vaccines using platforms such as mRNA and nanoparticles. This review outlines key mechanisms, vaccine targets, and platform innovations, and discusses major challenges and future directions for EBV vaccine development.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: